StevenLSchoenfeldMD

Diabetes, Lipid Metabolism

Vice President, Galectin Therapeutics

Dr. Schoenfeld is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Broad-based, international clinical drug development experience with small molecules and biologics.

Specialties: NASH, liver diseases, lysosomal storage diseases (LSD), Oncology, Osteoporosis, Hip Fracture Recovery, Diabetes, Inflammation, and Endocrine Clinical Drug Development.

11 successful 1st IND applications, 9 successful NDAs/MAAs prepared.

University of WashingtonFellowship, Endocrinology, Diabetes, and Metabolism, 1986 - 1989
New York Medical CollegeClass of 1983

William E. Upjohn Medal, “In recognition of Special Accomplishment” Issued by Pfizer, Inc., 2003

PubMed

99 citations
Cyclical Etidronate in the Treatment of Postmenopausal Osteoporosis: Efficacy and Safety After Seven Years of Treatment
Paul D. Miller, Nelson B. Watts, Angelo A. Licata, Steven T. Harris, Harry K. Genant
The American Journal of Medicine. 1997-12-01
36 citations
Systematic variation and differences in insulin-autoantibody measurements.
Terence J. Wilkin, Steven L Schoenfeld, Jose-Luis Diaz, Viggo Kruse, Ezio Bonifacio
Diabetes. 1989-02-01
70 citations
Nonprogression of subclinical beta-cell dysfunction among first-degree relatives of IDDM patients. 5-yr follow-up of the Seattle Family Study.
David K. McCulloch, Leslie J. Klaff, Steven E. Kahn, Steven L Schoenfeld, Carla J. Greenbaum
Diabetes. 1990-05-01